Testing Solutions for

Rapidly Detecting Influenza A&B

Best-in-Class Flu Diagnostics from the Fisher Healthcare Portfolio



Insight. Impact. Outcomes.

fisher healthcare
part of Thermo Fisher Scientific

Abbott ID Now (formerly Alere i)

The Abbott™ ID NOW™ System uses isothermal nucleic acid amplification technology to detect influenza A and B viral nucleic acids. The CLIA-waived method includes all of the necessary testing components, and the analyzer offers barcode technology and LIS connectivity. This multi-assay platform includes Influenza A and B, RSV, and Strep A.

Cat. No. 23-046-617 and 23-046-634

Clinical Outcomes
- Sensitive — True molecular test eliminates need for negative confirmation
- Precise — Accurate results help to avoid unnecessary antibiotic use

Operational Outcomes
- Simple — Easy-to-use, CLIA-waived test
- Fast — Results available within 13 minutes

Financial Outcomes
- Effective — Fast, accurate results reduce downstream costs
- Flexible — Multiple purchase options

Quidel Solana

The Quidel™ Solana™ Molecular Platform provides Influenza A and B results in 45 minutes and multiplexes up to 12 tests per run. The CLIA-moderate assay includes access to the Power of Virena and offers LIS/EMR connectivity. This multi-assay platform offers a variety of diagnostics, from bacterial infections to infectious diseases.

Cat. No. 23-043-111 and 23-043-107

Clinical Outcomes
- Precise — Highly sensitive molecular-based test for accurate results
- Safe — Helps to reduce the risk of unnecessary antibiotic use

Operational Outcomes
- Flexible — Offers STAT or batch testing
- Simple — Share results via LIS connectivity

Financial Outcomes
- Efficient — High sensitivity reduces the need for repeat testing
- Affordable — Multiple placement and purchase options; no need for multiple instrument platforms

Roche cobas Liat System

In just three steps, the Roche cobas™ Liat™ assays and analyzer automate the entire nucleic acid test (NAT) process: reagent preparation, target enrichment, inhibitor removal, nucleic acid extraction, amplification, real-time detection, and result interpretation. The system is CLIA-waived for Influenza A/B, RSV, and Strep A.

Cat. No. 23-312-198 and 23-312-200

Clinical Outcomes
- Confidence in making the right treatment decision at the time of the test – no confirmation needed
- Lab-standard sensitivity and specificity

Operational Outcomes
- Fast, easy operation with three simple steps
- Walkaway workflow and test results in 20 minutes or less
- Closed System concept, ideal for moving molecular out of the lab with decreased risk for contamination

Financial Outcomes
- No confirmation required
- Molecular CPT codes generally allow for higher reimbursement rate
- Capital and Placement options available



Sekisui Diagnostics Silaris

Influenza A&B Test

The Sekisui™ Silaris™ Influenza A&B Test is a molecular diagnostic test that uses the polymerase chain reaction (PCR) and lateral flow technology to qualitatively detect the presence of antibodies to influenza A and B viruses in approximately 30 minutes. The CLIA-waived test is performed on nasal swab specimens using the Silaris Dock device. Reagents can be stored at room temperature.

Cat. No. 22-321-116 and 22-321-115

Clinical Outcomes

- Accurate — clear information helps physicians provide targeted treatment
- Reliable — precise results help reduce inappropriate use of antibiotics

Operational Outcomes

- Easy — CLIA-waived test for point-of-care diagnosis and treatment
- Efficient — fast turnaround allows for prompt infection control measures

Financial Outcomes

- Simple — test reduces costs and need to send samples to a core or reference lab
- Affordable — cost effective with minimal capital outlay

Abbott DIGIVAL Reader

Abbott™ DIGIVAL™ Reader is a benchtop instrument that can objectively interpret results by using a camera to detect the presence of and identify a completed lateral flow assay, analyze the intensity of the test and control line, and display the results (positive, negative, or invalid) on the color touchscreen.

Cat. No. 23-046-680 and 23-046-682

Clinical Outcomes
- Accurate — objective results for more reliable diagnoses
- Effective — eliminates the variability of visually read tests

Operational Outcomes
- Simple — intuitive design for ease of use
- Flexible — choice of “read now” and “walk away” modes

Financial Outcomes
- Affordable — cost-effective assay and platform



BD Veritor Plus System

The BD™ Veritor™ Plus System is a rapid chromatographic immunoassay analyzer for the qualitative detection of Influenza A and B viral nucleoprotein antigens. The system is CLIA waived for nasal and nasopharygeal swabs and offers two modes: Analyze Now and Walk Away. This multi-assay platform includes Influenza A and B, RSV, and Strep A.

Cat. No. B256066, B256041, and B256045

Clinical Outcomes
- Accurate — High positive and negative percent agreement
- Fast — Get results in 10 minutes for prompt diagnosis

Operational Outcomes
- Easy — No need to incubate samples before testing
- Flexible — Works with multiple sample types and workflow options
- Safe — Print or download results to reduce the risk of reporting errors

Financial Outcomes
- Economical — Expanded storage holds up to 3,500 results, so you spend less on additional analyzers

Quidel Sofia 2

The Quidel™ Sofia™ 2 Analyzer accurately detects Influenza A and B from nasal swabs, nasopharyngeal swabs, and nasal aspirate/wash samples. Its CLIA-waived procedure can produce dual test results from a single sample. The instrument features an easy-to-use interface with customizable settings.

Cat. No. 23-043-086 and 23-043-070

Clinical Outcomes
- Clear — Eliminates the subjectivity of visually interpreted results
- Fast — Positive results in as little as three minutes
- Efficient — Make real-time treatment decisions for public health surveillance

Operational Outcomes
- Convenient — Offers “read now” and “walk away” options
- Adaptable — Multi-assay platform is approved for influenza A and B, RSV, Strep A, Lyme, and hCG

Financial Outcomes
- Flexible — Multiple placement or direct purchase options
- Economical — Prompt, type-specific results to help reduce unnecessary testing and overuse of antibiotics

Sekisui Diagnostics Acucy

Influenza A&B Test Kit

Accurate, simple, and affordable solution to Influenza A&B testing. Acucy™ Influenza A&B offers a best-in-class Flu A performance and provides an easy-to-use CLIA-waived procedure as well as definitive and standardized results. The included QC (2 additional tests for QC in each kit) removes the additional expense of performing external QC testing making this analyzer even more cost competitive.

Cat. No. 22-321-25 and 22-321-28

Clinical Outcomes
- Best-in-class Flu A sensitivity
- Definitive results reduce human error and repeat testing

Operational Outcomes
- Results within 15 minutes
- Read-Now mode for high throughput

Financial Outcomes
- No long-term contract
- QC included = major cost savings

Quidel QuickVue Influenza A&B Test

The Quidel™ QuickVue™ Influenza A+B Test detects and differentiates influenza A and B antigens directly from nasal swab and nasopharyngeal swab specimens. A single sample can be used to run both the QuickVue Influenza A+B Test and the QuickVue RSV10 Test.

Cat. No. 23-043-058

Clinical Outcomes

- Accurate — reliable results allow clinicians to take action with confidence
- Fast — reduce wait time and improve patient satisfaction

Operational Outcomes

- Simple — CLIA-waived testing doesn't require additional training
- Flexible — Works with multiple sample types
- Easy — Test with only 30 to 60 seconds of hands-on time

Financial Outcomes

- Economical — Accurate, cost-effective detection

Thermo Scientific Xpect Flu A&B Test

The Thermo Scientific™ Xpect™ Flu A & B Test detects influenza A and B antigens from human nasal wash, nasal swab, and throat swab specimens. It helps maintain efficiency and productivity with a simple two-step procedure that offers accurate results in as little as 15 minutes.

Cat. No. R24600

Clinical Outcomes

- Accurate — reliable results allow clinicians to take action with confidence

Operational Outcomes

- Flexible — Multiple specimen storage, collection, and transportation options
- Efficient — Less than one minute of hands-on time and a walk-away procedure

Financial Outcomes

- Economical — Accurate, cost-effective detection



Meridian Bioscience ImmunoCard STAT!

Influenza A&B Test

The Meridian Bioscience™ ImmunoCard STAT!™ FLU A&B Test is a CLIA-waived lateral flow immunoassay for the detection of Influenza A and B from nasal and nasopharyngeal swabs. It can also be used to test nasal aspirate and wash specimens.

Cat. No. 23-315-126

Clinical Outcomes

- Accurate — Reliable results allow clinicians to take action with confidence

Operational Outcomes

- Simple — CLIA-waived testing doesn't require additional training
- Fast — Results in 10 to 15 minutes

Financial Outcomes

- Economical — Accurate, cost-effective detection

Sekisui OSOM Ultra

The Sekisui™ OSOM™ Ultra Influenza *in vitro* rapid qualitative test detects Influenza A and B nucleoprotein antigens directly from nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens obtained from patients with signs and symptoms of respiratory infection.

Cat. No. 22-321-105

Clinical Outcomes
- Accurate — High positive and negative percent agreement
- Fast — Short turnaround time for prompt diagnosis

Operational Outcomes
- Simple — Four easy steps for results in 15 minutes
- Flexible — Works with multiple sample types

Financial Outcomes
- Economical — No capital costs
- Affordable — Priced competitively with other rapid diagnostic tests

Germaine Laboratories BioSign

Flu A&B Test

The Germaine™ Laboratories BioSign™ Flu A&B Test can detect the presence of influenza A and B antigens from a single specimen. The method is CLIA waived when used with nasal or nasopharyngeal swabs and CLIA moderate for nasal wash/aspirate specimens. This rapid test can produce results in 10 to 15 minutes.

Cat. No. 23-111-369

Clinical Outcomes
- Accurate — reliable results allow clinicians to take action with confidence
- Fast — reduce wait time and improve patient satisfaction

Operational Outcomes
- Simple — CLIA-waived tests produce results in 15 minutes
- Flexible — format and procedure allow testing in a variety of clinical settings

Financial Outcomes
- Economical — no capital costs
- Affordable — priced competitively with other rapid diagnostic tests

LifeSign Status

Influenza A&B Test

The LifeSign™ Status Influenza A and B test qualitatively detects influenza A and B as well as H1N1 (swine flu). The test is CLIA waived for nasal swab samples, and the kit includes flocked swabs for better specimen collection.

Cat. No. 23-264-783

Clinical Outcomes
- Accurate — Differentiates between influenza A and B with results that compare well to PCR

Operational Outcomes
- Simple — Features onboard sample extraction and an easy-to-read flip design
- Flexible — Works with multiple sample types

Financial Outcomes
- Economical — no capital costs

Visual Read Lateral Flow Tests

FLU MATRIX	Quidel QuickVue Influenza A&B Test	Thermo Scientific Xpect	Meridian Bioscience Immunocard STAT!
Catalog Number	**23-043-058**	**R24600**	**R24600**
Specimen Type	• Nasal Swab • Nasopharyngeal Swab	• Nasal Swab • Nasal Wash • Throat Swab	• Nasal Swab • Nasopharyngeal Swab • Nasal Aspirate/Wash
CLIA Status	Waived	Moderate	Waived (nasal and nasopharyngeal swabs); Moderate (wash/aspirate)
Test Methodology	Lateral Flow	Lateral Flow	Lateral Flow
Instrument Connectivity	No	N/A	No
Time to Result	10 minutes or sooner	15 minutes	15 minutes or sooner
Recommend Negative Confirmation	Yes	Yes	Yes
Comparison Method	PCR	Culture and PCR for discrepants	Culture and PCR
Sensitivity: A/B (May depend on sample type)	81.9%/80.9%	A+92.2% / B=97.8%	95.3% / 91.6% (culture) 89.2% / 86.4% (PCR)
Specificity: A/B (May depend on sample type)	97.8%/99.1%	100%	85.7% / 97.5% (culture) 99.4% / 99% (PCR)
Tests Per Kit	25	20	32
CPT Codes* **	87502 (Flu A and B)	87502 (Flu A and B)	FLU A (swab) - 87804QW, FLU B (swab) - 87804QW-59, FLU A (wash/aspirate) - 87804, FLU B (wash/aspirate) - 87804-59
Meets FDA Flu Reclassification Requirements	Yes	Yes	Yes
Other Tests Available	None	None	None

Visual Read Lateral Flow Tests

FLU MATRIX	Sekisui OSOM Ultra	Germaine Labs BioSign Influenza A&B Test	LifeSign Status Influenza A&B Test
Catalog Number	**22-321-105**	**23-111-369**	**23-264-783**
Specimen Type	• Nasal swab • Nasopharyngeal swab • Nasopharyngeal wash/aspirate	• Nasal swab • Nasopharyngeal swab • Nasopharyngeal wash/aspirate	• Nasal swab • Nasopharyngeal swab • Nasopharyngeal wash/aspirate
CLIA Status	Waived (nasal and nasopharyngeal swabs) Moderate (wash/aspirate)	Waived (nasal and nasopharyngeal swabs) Moderate (wash/aspirate)	Waived (nasal and nasopharyngeal swabs) Moderate (wash/aspirate)
Test Methodology	Lateral flow	Lateral flow	Lateral flow
Instrument Connectivity	No	No	No
Time to Result	• 10 minutes (positive) • 15 minutes (confirm negative)	• 10 minutes (positive) • 15 minutes (confirm negative)	• 10 minutes (positive) • 15 minutes (confirm negative)
Recommend Negative Confirmation	Yes	Yes	Yes
Comparison Method	Culture, PCR	RT-PCR	Culture, PCR
Sensitivity: A/B (May depend on sample type)	91.2%/82.4% (culture) 89.2%/86.4% (PCR)	96.7% (both A and B)	89.2–95.3%/82.4–91.6%
Specificity: A/B (May depend on sample type)	75.2%/88.3% (culture) 99.4%/99% (PCR)	91% (both A and B)	75.2–99.4%/88.3–99%
Tests Per Kit	25 (plus two for QC)	25	22 (includes positive and negative QC swabs)
CPT Codes* **	87804QW/87804QW-59	Influenza A 87084QW Influenza B 87084QW-59	87804 87804-59 (Used to indicate separate test)
Meets FDA Flu Reclassification Requirements	Yes	Yes	Yes
Other Tests Available	N/A	N/A	N/A

Analyzers

FLU MATRIX	Abbott DIGIVAL	BD Veritor Plus System	Quidel Sofia and Sofia 2	Sekisui Acucy
Catalog Number	**23-046-682**	**B256045 (Waived)** **B256041 (Moderate)**	**23-043-070**	**22-321-128**
Specimen Type	• Nasal swab • Nasopharyngeal swab	• Nasal swab • Nasopharyngeal swab	• Nasal swab • Nasopharyngeal swab • Nasopharyngeal wash/ aspirate	• Nasal Swab • Nasopharyngeal Swab
CLIA Status	Waived	Waived and moderate	Waived and moderate	Waived
Test Methodology	Lateral flow	Digital immunoassay (DIA)	Fluorescent immunoassay	Lateral Flow Reader
Instrument Connectivity	Yes — bidirectional	Veritor: No Veritor Plus: Yes	Yes, with real-time mapping and tracking capabilities	USB Drive and Third-Party
Time to Result	15 minutes	10 minutes	• 3 minutes (positive, Sofia 2) • 15 minutes (negative, Sofia and Sofia 2)	15 minutes
Recommend Negative Confirmation	Yes	Yes	Yes	Yes
Comparison Method	PCR	PCR	Culture	Composite comparator (culture and molecular)
Sensitivity: A/B (May depend on sample type)	87%/95.7%	81–83%/80–86%	90–99%/88–90%	A: 96.4% B: 82.3%
Specificity: A/B (May depend on sample type)	95.1%/99.5%	97–98%/99–100%	95–96%/96–97%	A: 96.0% B: 98.1%
Tests Per Kit	22	30	25	25
CPT Codes* **	87804 x 2	87804 (Flu A and B) 87807 (RSV) 87880 (Strep A)	87804QW (Flu A and B) 87807QW (RSV) 87880 (Strep A) 87880QW (Strep A+) 84703 (hCG) 86618QW 86618QW 86618QW (Sofia 2 Lyme IgM) 86618QW-59 (Sofia 2 Lyme IgG)	87804QW
Meets FDA Flu Reclassification Requirements	Yes	Yes	Yes	Yes
Other Tests Available	None Currently	• RSV • Strep A	• hCG (Sofia) • RSV (Sofia, Sofia 2) • Strep A (Sofia, Sofia 2) • Lyme (Sofia, Sofia 2)	Non currently

Molecular Instruments

FLU MATRIX	Abbott ID Now (formerly Alere i)	Quidel Solana	Sekisui Silaris	Roche cobas Liat System
Catalog Number	**23-046-634**	**23-043-107**	**22-321-116**	**23-312-198** **23-312-199** **23-312-200**
Specimen Type	• Nasal swab • Nasopharyngeal swab	• Nasal swab • Nasopharyngeal swab	• Nasal swab	Nasopharyngeal
CLIA Status	Waived	Moderate	Waived	Waived
Test Methodology	Nucleic acid amplification	Helicase-dependent amplification (HDA)	Reverse transcription-polymerase chain reaction (RT-PCR)	Real-Time PCR
Instrument Connectivity	Yes — uni- and bidirectional	Yes, with real-time mapping and tracking capabilities	No	Yes (with RALS, Telcor, or cobas 1000)
Time to Result	• 5 minutes (positive) • 13 minutes (confirm negative)	• 45 minutes (per run of 1–12 tests)	• 30 minutes	• 20 minutes
Recommend Negative Confirmation	No	No	No — uses reference method	No
Comparison Method	Molecular	Culture, PCR	FDA-approved molecular (Abbott ID Now)	Culture and PCR for discrepants
Sensitivity: A/B (May depend on sample type)	96.3%/100% (direct) 92.8%/100% (VTM)	98.6.%/100% (culture) 97.2%/100% (PCR)	97%/94%	A=100% / B=100%
Specificity: A/B (May depend on sample type)	97.4%/97.1% (direct) 98.5%/97.7% (VTM)	95.1.%/99.3% (culture) 96.7%/98.9% (PCR)	94%/99%	A = 96.8% / B=94.1%
Tests Per Kit	24	48	25	20

continued on next page

Molecular Instruments

CPT Codes* **	87502	87493 (C. diff) 87529 x 2/87798 (HSV 1&2/VZV) 87651/87998 (GAS/Strep Complete) 87661 (Trichomonas) 87502 (Flu A and B) 187798 x 2 (Bordetella Complete) 87077/87653 (Group B Strep: Vaginal/Rectal Swab) 87798 x 2 (RSV and hMPV)	87502QW (Influenza DNA Amp Probe)	87502 (Flu A and B)
Meets FDA Flu Reclassification Requirements	Yes	Yes	Yes	Yes
Other Tests Available	• RSV • Strep A	• C. difficile • HSV 1&2/VZV • Strep A, Strep Complete (A,C,G) • RSV/hMPV • Trichomonas • Group B Strep • Bordatella pertussis	None currently	None currently

*Approved VTM: BD/Copan VTM, Remel M4, Remel M4RT, Remel M5, Remel M6, or Copen ESwab

**Modifier, -QW, used to reflect CLIA-waived status for test

***The information being provided is for informational purposes only. There are no warranties, promises, or representations of any kind, expressed or implied, as to the nature, standard, or accuracy of the information being provided. This information does not purport to provide legal or certified coding advice. Policies regarding appropriate coding and payment levels can vary greatly from payer to payer and change over time, therefore it is the individual provider's responsibility to determine appropriate coding, charges, and claims for a particular service as required under federal and state law. It is strongly recommended that providers contact their contracted payers to determine appropriate coding and charge or payment levels prior to submitting claims.

As of November 11, 2019, these products meet FDA reclassification requirements. Policies regarding reclassification can vary and change over time, therefore it is the individual provider's responsibility to preform due diligence and make an individual determination regarding a product's classification.



In the United States
Order online: fisherhealthcare.com
Fax an order: 1-800-290-0290
Call customer service: 1-800-640-0640

fisher healthcare
part of **Thermo Fisher Scientific**